This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Indrajit Bandyopadhyay
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Hold TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
CAH Stock Up Nearly 7% This Year: Is Now the Time to Buy?
by Zacks Equity Research
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
Phibro Animal Health Stock Up 87.5% in a Year: What's Driving the Rise?
by Zacks Equity Research
PAHC stays on investors' radar due to its Animal Health business and potential in emerging markets.
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
by Zacks Equity Research
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
by Zacks Equity Research
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
by Zacks Equity Research
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.
VEEV Stock Gains Following Latest Availability of HCP Access Data
by Zacks Equity Research
Veeva Systems aims to provide immediate value for commercial operations and data analytics teams via CRM Pulse, which provides quarterly HCP access data.
Cooper Companies Q1 Earnings In Line, Revenues Miss, Stock Falls
by Zacks Equity Research
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
ALGN Stock Gains on Addition of Upgrades to the iTero Lumina Solutions
by Zacks Equity Research
Align Technology adds restorative capabilities to the iTero Lumina Solutions - the iTero Lumina intraoral scanner and the iTero Lumina Pro dental imaging system.
Is it Worth Adding ResMed Stock to Your Portfolio Now?
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
by Zacks Equity Research
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
FMS Stock Gains Following Stake Sale to Reduce Debt & Boost Profit
by Zacks Equity Research
Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
by Zacks Equity Research
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
Reasons to Retain Envista Stock in Your Portfolio for Now
by Zacks Equity Research
NVST's impressive long-term growth initiatives appear promising. Yet, a leveraged balance sheet is worrisome.
Should Labcorp Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
Bruker Stock to Benefit From the Launch of X4 POSEIDON Benchtop XRM
by Zacks Equity Research
BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications.
SYK Stock Declines Despite Steri-Shield Launch to Boost OR Portfolio
by Zacks Equity Research
Stryker launches Steri-Shield 8, a cutting-edge PPE system with enhanced fit, visibility and protection, reinforcing its leadership in medical safety.
Omnicell Gains 41.6% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.
5 Broker-Loved Stocks to Keep an Eye on Amid Trade Tensions
by Maharathi Basu
Investors should monitor stocks like Cardinal Health, DXC Technology, Cross Country Healthcare, Avnet and Asbury for high returns.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.